Gilead profit tops expectations despite lower COVID drug sales, outlook raisedBusiness, TherapeuticsGilead Sciences Inc. on Thursday posted a higher-than-expected third-quarter profit on the back of strong demand for its HIV and cancer drugs, which helped offset lower sales of its COVID-19 antiviral drug and acquisition expenses. Read more October 27, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/07/Gileads-COVID-19-antiviral-remdesivir-gets-conditional-EU-clearance-Reuters-7-3-20.jpeg 246 370 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-10-27 18:46:342022-10-28 11:11:01Gilead profit tops expectations despite lower COVID drug sales, outlook raised
